SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Brain shaped white jigsaw puzzle on blue background. Mental health and problems with memory.
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Young White Woman at home Holding Two Pain Killer Pills in Her Hand Palm After Spilling from Bottle and Glass of Water. Concept of Pain Relief, Addiction to Opioids and NSAIDs
Pain
Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a significant concern in the analgesic field.
January 22, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson
Earnings
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus away from enormous takeovers to single-digit billion buy outs.
January 22, 2025
 · 
3 min read
 · 
Annalee Armstrong
Man preparing his GLP-1 injection
GLP-1
The Good, the Bad and the Ugly of GLP-1s: Study
Computational research conducted by scientists from Washington University in St. Louis shows that GLP-1 agonists can have mental and cognitive health benefits but may also harm the kidneys and pancreas.
January 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Nabs Another $590M from HHS for mRNA-Based Bird Flu Vaccines
The funding, which follows the $176 million the government awarded Moderna in June 2024, aims to get mRNA vaccines ready before bird flu strains currently circulating in the wild and on farms can potentially cause human outbreaks.
January 21, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Facade of AstraZeneca's office in Shanghai, China
FDA
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the 15 products to be subject to IRA-prescripted price negotiations for Medicare this year.
January 17, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market just yet, forcing the company to “significantly reduce expenses.”
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Entrance of the FTC in Washington, DC
Policy
Pharmacy Benefits Managers Netted Extra $7.3B by Inflating Drug Prices: FTC
A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare and commercial claims alike.
January 15, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Eli Lilly Campus in San Diego
Earnings
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
January 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
Pipeline
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.
January 14, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Pictured: Eli Lilly's headquarters in Indianapolis
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
3D illustration of an antibody-drug conjugate
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More